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BACKGROUND. To date, the standard treatment for patients who have carcinoma
of unknown primary site has not been established.
METHODS. In this randomized Phase II study, 66 previously untreated patients
(33 patients per arm) with carcinomas of unknown primary site received cisplatin
(35 mg/m2) and gemcitabine (1000 mg/m2) with either paclitaxel (70 mg/m2) or
vinorelbine (25 mg/m2), and all drugs were administered intravenously on Days
1 and 8 of a 21-day cycle. Twenty-nine patients (44%) presented with 2 involved
sites. The pathologic diagnosis was mainly adenocarcinoma (48 patients; 72.7%)
and squamous carcinoma (7 patients; 10.6%).
RESULTS. In the first arm, 16 patients (48.5%) experienced an objective response,
and 9 patients (27.2%) had disease stabilization. In the vinorelbine-containing arm,
14 patients (42.3%) experienced an objective response, and 8 patients (24.2%) had
disease stabilization. The median response duration and the median time to pro-
gression were similar in both treatment arms; the median overall survival was 9.6
months (95% confidence interval, 7.11–12.09 months) for patients who received the
cisplatin/gemcitabine/paclitaxel regimen and 13.6 months (95% confidence inter-
val, 6.61–20.59 months) for patients who received the vinorelbine combination.
Grade 3 and 4 toxicities were more frequent in the paclitaxel-containing arm.
CONCLUSIONS. Both combinations satisfied the 2-step design, demonstrating anti-
tumor activity without relevant differences in response rates or response duration;
however, the vinorelbine-containing regimen yielded superior results both in terms
of overall survival (13.6 months vs 9.6 months) and in terms of treatment tolerabil-
ity. Therefore, according to a pick the winner attitude, the combination of cisplatin/
gemcitabine/vinorelbine may be considered in the design of future randomized,
Phase III trials for patients with carcinomas of unknown primary site. Cancer
2006;107:2898–905.  2006 American Cancer Society.
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C arcinomas of unknown primary site (CUP) repre-sent a distinct but heterogeneous group of meta-
static tumors, accounting for 2.3% to 4.2% of all
cancers1 in which the primary site of origin cannot be
detected during pretreatment evaluation.2 Despite sig-
nificant improvement in many diagnostic techniques,
eg, tumor imaging and pathologic evaluation of tissue
samples, CUP represents an extremely challenging
clinical entity in terms of treatment. Indeed, the real
impact of chemotherapy on the natural history of CUP
remains to be determined, and the median survival of
patients with CUP rarely exceeds 12 months.3 Al-
though cisplatin-based regimens have yielded better
response rates (usually in the range from 23% to 39%),
median survival results remain unsatisfactory, ranging
from 5 months to 9 months,4 and no standard treat-
ment has been established to date.5
The recent availability of newer, broadly active
chemotherapeutic agents (eg, gemcitabine, vinorel-
bine, and the taxanes, among others) has created new
options in the therapeutic strategy for patients with
CUP. Here, we report the results of a multicenter, ran-
domized, Phase II trial evaluating the efficacy and tox-
icity profile of the combination of cisplatin (Pfizer
Pharmaceuticals, New York, NY) and gemcitabine (Eli-
Lilly, Indianapolis, IN) combined either with vinorel-
bine (PierreFabre Medicament, Castres Cedex, France)
or with paclitaxel (Bristol-Myers Squibb, Princeton, NJ)
for the treatment of CUP.
MATERIALS AND METHODS
Diagnostic Workup
Patients with histologically (or cytologically) documen-
ted, metastatic carcinoma were considered eligible for
the current study when the following diagnostic proce-
dures did not allow a primary origin to be identified:
complete history and thorough physical examination,
blood chemistry (including, in men, serum tumor
marker for prostate-specific antigen [PSA], a-fetopro-
tein, and b-human chorionic gonadotropin), urinalysis,
mammography in women, thoracic and abdominopel-
vic computed tomography scans, bone scan, and symp-
tom- or sign-oriented imaging or endoscopic studies.
Patients were enrolled if light microscopic pathologic
analysis showed a well or poorly differentiated adeno-
carcinoma, a poorly differentiated carcinoma, or any
squamous cell carcinomas. Specific pathologic analyses
were mandatory to rule out lymphomas (ie, staining for
leukocyte common antigen), malignant melanoma (ie,
staining for both S100 and HMB45), extragonadal germ
cell neoplasms (ie, staining for both a-fetoprotein and
b-human chorionic gonadotropin), sarcomas (ie. stain-
ing for cytokeratins and vimentin), neuroendocrine
tumors (ie, staining for chromogranin and synaptophy-
sin), and prostatic adenocarcinomas in men (ie, staining
for PSA).
PATIENTS
Along with a histologically (or cytologically) con-
firmed diagnosis of CUP, eligibility criteria included
measurable disease, an Eastern Cooperative Oncol-
ogy Group (ECOG) performance status (PS) 2, age
between 18 years and 75 years, a life expectancy
12 weeks, and written informed consent obtained
according to the institutional requirements.
Patients also were required to have adequate organ
function, which was defined by the following parame-
ters: white blood cells 3000/mL, platelets 100,000/mL,
hemoglobin 9.5 g/dL, bilirubin <1.5 mg/dL, aspartate
and alanine aminotransferase levels <3 times the upper
limit of normal, and creatinine <2.0 mg/dL. The pre-
sence of significant comorbidities, including uncon-
trolled diabetes, active systemic infections, a history of
severe coronary artery disease or myocardial infarction
within the last 6 months, psychiatric conditions, the
presence of central nervous system metastases, a his-
tory of other cancers within the previous 5 years (ex-
cept localized non-melanomatous skin cancer or well-
managed in situ uterine carcinoma), and pregnancy or
lactation, were considered exclusion criteria. Patient
subgroups that were suitable for well-defined treat-
ments (ie, women with adenocarcinoma involving axil-
lary lymph nodes as the only site of disease, women
with papillary serous carcinoma of the peritoneum,
patients with squamous cell carcinoma that involved
either cervical or inguinal lymph nodes only, patients
with poorly differentiated carcinomas that suggested ger-
minal tumors and with elevated levels of b-human cho-
rionic gonadotropin and/or a-fetoprotein, and patients
with carcinoma that involved a single, potentially re-
sectable site) also were excluded from enrolment.
Treatment Schedule
In the first treatment arm (cisplatin, gemcitabine and
vinorelbine [CGV]), vinorelbine (25 mg/m2) was added
to a cisplatin (35 mg/m2) and gemcitabine (1000 mg/
m2) combination and all drugs were administered intra-
venously on Days 1 and 8 of a 21-day cycle. Gemcitabine
was administered over 30 minutes before cisplatin.
In the second treatment arm (cisplatin, gemcita-
bine, and paclitaxel [CGT]), paclitaxel (70 mg/m2) given
as a 1-hour intravenous infusion, replaced the vinorel-
bine. Cisplatin and gemcitabine were delivered as speci-
fied above for the CGV arm.
In the CGT arm, all patients received premedica-
tion with steroids and antihistamine drugs according
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to the practice of each center. Antiemetic treatment
was provided at each researcher’s discretion.
A minimum of 3 cycles was required before the
first tumor response assessment; then, a complete
reevaluation was performed every 3 cycles of chemo-
therapy employing the same staging procedures that
identified the metastatic sites of disease at baseline.
The study treatments were administered mainly on
an outpatient basis.
Assessment of Response and Toxicity
Complete response (CR), partial response (PR), stable
disease (SD), and progressive disease (PD) were as-
sessed according to World Health Organization crite-
ria.6 A CR was defined as complete regression of all
lesions and signs and symptoms of disease. A PR was
defined as a reduction 50% in the sum of the product
of the 2 greatest dimensions of all measurable lesions,
including partial healing of lytic lesions or reduction in
the number of the uptake areas, that lasted 2 months.
SD was considered a reduction <50% or an increase
<25% in the sum of the product of the same 2 greatest
dimensions of measurable lesions that lasted 3
months. PD was defined as an increase >25% in the
sum of the product of the 2 greatest dimensions of all
measurable lesions and/or the appearance of new
lesions. Chemotherapy-related toxic effects were re-
corded according to the National Cancer Institute’s
Common Toxicity Criteria, version 3.0,7 at every cycle
and at the end of treatment.
Statistical Considerations
The primary endpoint of this randomized Phase II
study was the evaluation of the overall response rate
(ORR); secondary objectives were the analysis of the
toxicity profile, the time to progression (TTP), the
duration of response, the overall survival (OS) for the
2 treatment arms, the correlation between disease
characteristics (extension, sites of disease, etc), and
clinical and/or pathologic parameters. A noncom-
parative analysis of these parameters in both treat-
ment arms was performed to select the best regimen
according to a pick the winner attitude. For this ran-
domized Phase II study, the sample size was calcu-
lated by applying a Simon 2-step minimax design.8
Considering a 40% ORR clinically important with
a type-1 error of 5% and a type-2 error of 20%, 18
patients in each treatment arm were required for ini-
tial treatment. If 5 of the first 18 patients obtained
an objective response, then accrual would continue
until the final enrolment of a total of 33 patients per
arm. The TTP was calculated the date chemotherapy
was started until there was clinical and/or radiologic
evidence of PD; OS was calculated from the date
chemotherapy was started until the date of death or
last documented follow-up. All data concerning TTP
and OS were analyzed according to the Kaplan-Meier
method9 by using the SPSS statistical software pack-
age. Finally, to determine whether some clinical pa-
rameters (patient age, ECOG PS and the number of
metastatic sites) could be identified as prognostic
factors, their possible impact on response rate and
survival was evaluated by performing a multivariate
analysis with a logistic regression model and a Spear-
man correlation model, respectively.
RESULTS
Patient Characteristics
From March 2001 to August 2003, 66 chemotherapy-
naive patients were assigned using blocked randomi-
zation to both treatment arms (33 patients in each
arm). Written informed consent was obtained from
all enrolled patients. All patients were assessable for
response and toxicity.
Patients’ baseline characteristics, which were well
balanced between the 2 treatment arms, are summar-
ized in Table 1. Fifty-two patients were men (78.8%), 14
patients were women (21.2%), and the median patient
age was 60.5 years. The ECOG PS was 0 in 22 patients
(33.3%), 1 in 42 patients (63.6%), and 2 in the remain-
ing 2 patients (3%).
Twenty-nine of 66 patients (43.9%) presented with
2 metastatic sites, with lymph nodes the most fre-
quent disease localization (82%), followed by bone
(27.3%) and liver (27.3%). Histologic types were adeno-
carcinoma in 48 patients (72.7%), squamous cell in 7
patients (10.6%), anaplastic in 5 patients (7.6%), epithe-
lioid in 5 patients (7.6%) and medullary in 1 patient
(1.5%).
Response
In total, 297 cycles (155 cycles in the CGT arm; 142
cycles in the CGV arm) were administered with a me-
dian of 4 cycles of treatment per patient in the vinorel-
bine-containing arm and 5 cycles per patient in the
paclitaxel-containing arm. According to the research
protocol, we proceeded to the second step of the study
after obtaining 5 objective responses in the first 18
patients in each treatment arm. In the CGT arm, 16
patients achieved an objective response (48.5%), 1 pa-
tient achieved a CR (3%) and 15 patients achieved a PR
(45.5%); in the CGV arm, the ORR was 42.3%, and there
were 3 CRs (9%) and 11 PRs (33.3%).
Nine patients in the CGT arm and 8 patients in
the CGV arm had SD as their best response (27.3%
and 24.2%, respectively), whereas PD occurred in 8
patients (24.2%) in the CGT arm and in 11 patients
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(33.3%) in the CGV arm (Table 2). The median re-
sponse duration was similar in the 2 treatment arms:
7.5 months (95% confidence interval [95% CI], 5.6–
9.4 months) in the CGV arm (mean, 10.28 months;
range, 1–21.4 months) and 7.4 months (95% CI, 6.9–
8.0 months) in the CGT arm (mean, 9 months; range,
2.2–16.7 months).
The median OS was 13.6 months (95% CI, 6.61–
20.59 months; mean, 12.14 months; range, 1.03–21.5
months) for patients who received the CGV combina-
tion. For patients who received the CGT combina-
tion, the median OS was 9.6 months (95% CI, 7.11–
12.09months; mean, 10months; range, 1.5–16.73months).
The median TTP also was similar in both treatments
arms (6 months). The Kaplan-Meier curves for OS and
TTP for each treatment arm are represented in Figures 1
and 2, respectively.
With reference to clinical parameters, such as prog-
nostic factors, no correlation between the response rate
and any clinical parameter was observed. However,
there was a significant correlation between OS and PS
(Spearman r, 0.263; 2-tailed P < .05), so that OS de-
creased with increasing PS.
Compliance With Treatment and Toxicity
The tolerability of the 2 treatment arms was acceptable.
Overall, grade 3 and 4 toxicities were more frequent in
the CGT arm, with 16 patients (48.5%) experiencing
grade 3 or 4 adverse events versus 11 patients (33.3%)
in the CGV arm. In the CGTarm, the most common he-
matologic toxicity was anemia, which occurred in 15
patients (45.5%) and was grade 3 or 4 in 3 patients
(9.1%). In the CGV arm, the most common hematologic
toxicity was neutropenia, which was experienced by 14
patients (42%) and was grade 3 or 4 in 4 patients (12%).
TABLE 2
Response
Response (N = 66
assessable patients)
No. of patients (%)
CGT CGV
Overall patient
population
CR 1 (3) 3 (9) 4 (6)
PR 15 (45.5) 11 (33.3) 26 (39.4)
SD 9 (27.3) 8 (24.2) 17 (25.8)
PD 8 (24.2) 11 (33.3) 19 (28.8)
C indicates cis-diamminedichloroplatinum; G, gemcitabine; T, paclitaxel; V, vinorelbine, CR, com-
plete response; PR, partial response; SD, stable disease; PD, progressive disease.
TABLE 1
Patient Characteristics
Characteristic
No. of patients (%)
Total CGT CGV
Total enrolled 66 (100) 33 (50) 33 (50)
Assessable for activity 66 (100) 33 (50) 33 (50)
Assessable for toxicity 66 (100) 33 (50) 33 (50)
Age, y
Median 60.5 60 61
Range 31–75 33–75 31–75
Sex
Men 52 (78.8) 25 (75.5) 27 (81.8)
Women 14 (21.2) 8 (24.3) 6 (18.2)
ECOG PS
0 22 (33.3) 10. (30.3) 12 (36.4)
1 42 (63.6) 22 (66.7) 20 (60.6)
2 2 (3) 1 (3) 1 (3)
Metastatic sites
1 37 (56) 19 (57.6) 18 (54)
2 16 (24) 8 (24) 8 (24)
3 13 (20) 6 (18.2) 7 (21)
Site of disease
Lung 16 (24) 6 (18.2) 10 (30)
Lymph nodes 54 (82) 29 (87.9) 25 (75.7)
Bone 18 (27.3) 7 (21) 11 (33.3)
Liver 18 (27.3) 8 (24) 10 (30.3)
Pleura 6 (9.1) 3 (9.1) 3 (9.1)
Skin 1 (1.5) 1 (3) 0
Pancreas 3 (4.5) 3 (9.1) 0
Other 8 (12.1) 3 (9.1) 5 (15)
Histologic type
Adenocarcinoma 48 (72.7) 25 (75.7) 23 (73)
Anaplastic carcinoma 5 (7.5) 3 (9.1) 2 (6.1)
Squamous cell carcinoma 7 (10.6) 4 (12) 3 (9.1)
Medullary carcinoma 1 (1.5) 0 1 (3)
Epithelioid carcinoma 5 (7.6) 1 (3) 4 (12)
C indicates cis-diamminedichloroplatinum; G, gemcitabine; T, paclitaxel; V, vinorelbine; ECOG PS,
Eastern Cooperative Oncology Group performance status.
FIGURE 1. Kaplan-Meier estimates of overall survival. VNR indicates vinor-
elbine; TXL, paclitaxel.
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No febrile neutropenia was reported. Details about
hematologic toxicity are reported in Table 3.
Among nonhematologic toxicities, episodes of nau-
sea and emesis prevailed in both treatment arms (15
grade 1 or 2 episodes; 1 grade 3 or 4 episode), although
they were more frequent in the CGTarm (8 grade 1 or 2
episodes; 1 grade 3 episode) than in the CGV arm (7
grade 1 or 2 episodes; 0 grade 3 or 4 episodes). Nonhe-
matologic toxicities are reported in Table 4.
In the paclitaxel-containing arm, there was a sin-
gle treatment withdrawal (caused by the onset of
grade 3 cardiac toxicity), and there were 5 25%-dose
reductions (2 caused by thrombocytopenia and 3
caused by renal toxicity, neutropenia, and nausea/
emesis, respectively); whereas, in 2 other patients the
scheduled dose for Day 8 was omitted (because of
anemia and thrombocytopenia, respectively).
In the vinorelbine-containing arm, no treatment
withdrawal was observed; whereas there were 7 25%-
dose reductions (caused by thrombocytopenia, diar-
rhea, stomatitis, renal toxicity, neutropenia, nausea/
emesis, and anemia in 1 patient each). In 9 patients,
the scheduled dose for Day 8 was omitted (in 4
patients because of thrombocytopenia, in 3 patients
because of neutropenia, and in 2 patients because of
nausea/emesis and anemia).
DISCUSSION
CUPs constitute a heterogeneous and relatively rare
group of malignancies. The survival of patients with
CUP can vary mainly on the basis of histology, num-
ber and sites of disease, PS, and sex. For example,
patients who present with neuroendocrine carcinoma
or squamous cell carcinoma that infiltrates cervical
lymph nodes who have <2 sites of disease, and
lymph nodes as the only metastatic site, a good PS
(<1) and who also are women are characterized by a
more favorable prognosis. Conversely, adenocarcino-
mas and liver metastases are associated with poorer
survival.1,10
The optimal first-line treatment for patients with
CUP remains to be determined.2,5 Previous trials of
noncisplatin-based combinations, including 5-fluor-
ouracil, cyclophosphamide, and doxorubicin, yielded
disappointing results with response rates ranging
from 10% to 33% and with median survival ranging
from 4 months to 9 months.11–17 Although cisplatin-
based regimens have yielded better response rates
(usually in the range of 23–39%), median survival
results remain unsatisfactory, ranging from 5 months
to 9 months.14,15,17–19
Until the 1990s, only 1 of 3 published Phase III,
randomized trials in which a cisplatin-based regimen
was compared with a noncisplatin-based regimen re-
ported a survival advantage for patients who received
cisplatin.14,15,20 However, the suboptimal design of
those Phase III studies, including small sample sizes
FIGURE 2. Kaplan-Meier estimates of time to progression. VNR indicates
vinorelbine; TXL, paclitaxel.
TABLE 3
Hematologic Toxicity (Grades 3 and 4)
Toxicity (N = 66
assessable patients)
No. of patients (%)
CGT CGV Overall patient population
Neutropenia 6 (18.2) 4 (12) 10 (15)
Anemia 3 (9.1) 3 (9.1)* 6 (9)
Thrombocytopenia 4 (12) 3 (9.1) 7 (10.6)
C indicates cis-diamminedichloroplatinum; G, gemcitabine; T, paclitaxel; V, vinorelbine.
* Grade 3.
TABLE 4
Nonhematologic Toxicity (Grades 3 and 4)
Toxicity (N 5 66
assessable patients)
No. of patients (%)
CGT CGV Overall patient population
Nausea/emesis 1 (3)* 0 1 (1.5)
Diarrhea 0 1 (3)* 1 (1.5)
Mucositis 1 (3)* 0 1 (1.5)
Neurotoxicity 0 0 0
Hepatotoxicity 0 0 0
Asthenia 0 0 0
Cardiotoxicity 1 (3)* 0 1 (1.5)
Nephrotoxicity 0 0 0
C indicates cis-diamminedichloroplatinum; G, gemcitabine; T, paclitaxel; V, vinorelbine.
* Grade 3.
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(55–95 patients), did not allow the authors to reach
definitive conclusions about the role of cisplatin in
the treatment of CUP.
Given the lack of randomized Phase III trials, it
seemed necessary for us also to focus our attention
on published Phase II studies. Indeed, Table 5 lists
the more recent and/or important Phase II trials of
different chemotherapy regimens in the treatment of
CUP and includes the current study. It seems perti-
nent to remark here that, when reviewing the litera-
ture with clinical data based mainly on these kinds
of studies, all results must be reviewed with a skepti-
cal eye and comparisons between different Phase II
studies may not be accurate.
In the last decade, the availability of new, broadly
active compounds, such as taxanes, vinorelbine, gemci-
tabine, and irinotecan, has represented an important
gain in the management of CUP. In a Phase II trial,
Briasoulis et al21 evaluated the combination of carbo-
platin plus paclitaxel in 77 patients with CUP
(including 33 patients with liver metastases, bone me-
tastases, or multiorgan metastases). The ORR was
38.7% (CR rate, 20%) and the median OS was 13
months in the entire population and 10 months in the
poor-prognosis group (visceral or disseminated metas-
tases). It is noteworthy that the 68.4% of patients who
presented with peritoneal carcinomatosis may have
contributed to the better results. A large group of
patients with CUP (396 patients), excluding favorable
subsets, was treated with taxane-containing regimens
in 5 consecutive Phase II trials by the Minnie Pearl
Cancer Research Network.22–25 Overall, those 5 studies
had an ORR of 30%, a median OS of 9.1 months, a pro-
gression-free survival of 5 months, 1-year and 2-year
survival rates of 38% and 19%, respectively. The authors
compared their results with historic data from 45 pro-
spective trials (1515 patients) and with retrospective
reviews (31,419 patients), which showed that the 1-year
and 2-year survival rates were prolonged significantly.26
Within the group of new agents, gemcitabine can
be considered a good candidate for polychemotherapy
regimens in the treatment of CUP because of its wide
spectrum of activity and good tolerability profile. Initi-
ally, this drug was given as second-line treatment.27
More recently, on the basis of these encouraging
results published in 2001 and confirmed in 2005,28
gemcitabine has been investigated more largely inves-
tigated in the first-line setting.
Balana et al29 conducted a Phase II study in 30
patients who had CUP with poor prognostic features
TABLE 5
Recent Phase II Studies in Patients with Cancer of Unknown Primary Origin (With Taxane- and
Nontaxane-based Chemotherapy)
Author and year of publication No. of patients Regimen Response rate (%)
Median survival
(Months)
Briasoulis et al, 200021 77 CbT 38.7 13
Greco et al, 200022 71 CbET 48 11
Greco et al, 200023 26 CDoc 26 8
47 (Sequential) CbDoc 22 8
Dowell et al, 200134 34 CbE 19 8.4
TFL 19 6.5
Greco et al, 200224 120 CbGT 25 9
Balana et al, 200329 30 CEG 36.6 7.2
Culine et al, 200330 80 GC 55 8
IC 38 6
Greco et al, 200425 132 CbET GI 30 9.1
Pouessel et al, 200435 36 DocG 40 10
Piga et al, 200431 102 CbEA 26.5 9
Park et al, 200436 37 TC 42 11
El-Rayes et al, 200537 22 CbT 23 6.5
Schneider et al, 200538 27 CbGCape 41 6.5
Huebner et al, 200532 92 CT 21.6 10.7
GV 21.4 6.9
Pittman et al, 200539 50 GCb 30 8.1
Varadhachary et al 200540 16 (5 2nd line) GOx 36 NR
Palmeri et al (current study) 66 CGT 48.5 9.6
CGV 42.3 13.6
Cb indicates carboplatin; T, paclitaxel; E, etoposide; C, cis-diamminedichloroplatinum; Doc, docetaxel; F, fluorouracil; L, leucovorin; G, gemcitabine; I, irinote-
can; A, doxorubicin; Cape, capecitabine; Ox, oxaliplatin; NR, not reported; V, vinorelbine.
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(10% of patients had brain metastases, 30% of patients
had bone metastases and 20% of patients had liver me-
tastases) to evaluate a regimen of cisplatin, etoposide
and gemcitabine every 21 days. Those investigators
reported an ORR of 36.6% and a median survival of
7.21 months with grade 3 or 4 neutropenia in 60% of
patients.
In the study of Culine et al,30 80 patients (60% with
poor prognostic features) were randomized to receive ei-
ther cisplatin in combination with gemcitabine (GC) or
irinotecan (IC). The reported ORR was 55% in the GC
arm and 38% in the IC arm and the median survival
was 8 months and 6 months, respectively, with an unfa-
vorable toxicity profile in the IC group (2 toxic deaths
from septic shock).
In 2004, Piga et al31 confirmed response and sur-
vival data when using a platinum-containing regimen
(carboplatin, doxorubicin, and etoposide) in a Phase II
study of 102 patients with CUP. An ORR of 26.5% and
an OS of 9 months (progression-free survival, 4 months)
were reported, whereas the main toxicity was grade 3 or
4 hematologic toxicity, which was reported in 57.8% of
patients.
Vinorelbine has shown good activity in patients
with lung, breast, head/neck, ovarian and uterine car-
cinomas and has an acceptable toxicity profile. Few
studies have evaluated the role of this drug in the treat-
ment of CUP. Recently, in a randomized Phase II trial
results that have been published only in an abstract
form, Huebner et al32 treated 92 patients with CUP
using either paclitaxel plus carboplatin or gemcitabine
plus vinorelbine. In those 2 treatment arms, the ORR
was 21.6% and 21.4%, respectively; the median OS was
10.7 months and 6.9 months, respectively; and the me-
dian progression-free survival was 6.4 months and
4 months, respectively.
Because of this background and considering that
most CUPs have their origin either in the pancreas or
in the lung,33 there was a strong rationale for designing
a study in which cisplatin and gemcitabine were com-
bined with either paclitaxel or vinorelbine. Overall, in
the current study, the patients were a good prognostic
group for CUP because of the following characteristics:
relatively young age (60 years), good PS (0 or 1 for
nearly all patients), prevalence of histology with a bet-
ter prognosis (adenocarcinoma, 72.7%; squamous cell
carcinoma, 10.6%), relatively few patients with liver
involvement (27.3%) and many patients with only 1
metastatic site (56%).
In this cohort both combinations, CGT and CGV,
satisfied the 2-step design and demonstrated antitu-
mor activity without any relevant differences observed
between them in terms of ORR (48.5% vs 42.3%) or
response duration (7.5 months vs 7.4 months). How-
ever, the CGV arm yielded superior results in terms of
both OS (13.6 months vs 9.6 months) and treatment
tolerability. Grade 3 and 4 neutropenia was only ob-
served in 18.2% of patients on the CGTarm and in 12%
of patients on the CGV arm. No febrile neutropenia
was observed. Nausea and emesis, which generally
were mild, were more frequent in the CGT group than
in the CGV group. No toxic deaths were observed.
Our findings confirm that cisplatin, gemcitabine,
paclitaxel and vinorelbine are active in patients with
CUP. Even though survival is not an endpoint for a
Phase II study, the survival results observed for the
vinorelbine-containing combination appear to be
extremely noteworthy, because they match the best
results reported in the literature to date. Furthermore,
the good tolerability profile of the vinorelbine-contain-
ing combination is a fundamental element to take into
account when treating patients with a poor life expect-
ancy, like that for patients with CUP. It must be taken
into consideration that, as mentioned above, patient
selection can interfere significantly with the results of
a randomized Phase II study, depending on the prog-
nostic characteristics of the patients who are selected.
In conclusion, through lack of a deeper knowledge of
the biologic and molecular characteristics of these par-
ticular neoplasms and according to a pick the winner
attitude, we believe that the combination of CGV de-
serves consideration as an experimental arm in the
design of future randomized, Phase III trials for pa-
tients with CUP.
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